Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Blinded, Multi-site, Pilot Study to Evaluate Adenosine 2A Receptor Agonist (REGADENOSON) in the Rehabilitation of Marginal Donor Lungs.

NCT04521569 is registered in ClinicalTrials.gov with University of Maryland, Baltimore as lead sponsor.

NCT NCT04521569
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04521569 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Blinded, Multi-site, Pilot Study to Evaluate Adenosine 2A Receptor Agonist (REGADENOSON) in the Rehabilitation of Marginal Donor Lungs.
Lead sponsor
University of Maryland, Baltimore
Phase
Phase 1
Overall status
Completed
Start date
June 22, 2020
Completion date
July 31, 2024
Enrollment
47 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

lung transplant